Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -9.93
- Piotroski Score 3.00
- Grade Buy
- Symbol (TPST)
- Company Tempest Therapeutics, Inc.
- Price $0.89
- Changes Percentage (-0.53%)
- Change -$0
- Day Low $0.87
- Day High $0.92
- Year High $6.00
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/17/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.72
- Trailing P/E Ratio -1.81
- Forward P/E Ratio -1.81
- P/E Growth -1.81
- Net Income $-29,491,000
Income Statement
Quarterly
Annual
Latest News of TPST
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Tempest Therapeutics, Inc. (TPST) Stock Price, News, Quote & History - Yahoo Finance
Tempest Therapeutics, Inc. is a biotech company focusing on developing innovative cancer treatments using small molecules. Their clinical programs include TPST-1495 and TPST-1120 for cancer treatment,...
By Yahoo! Finance | 4 months ago
